Novo Nordisk bets on innovative insulin: "Many doctors said we were crazy"

Insulin has made its big comeback in Novo Nordisk's diabetes pipeline despite pricing pressure in the insulin market. Chief Science Officer Mads Krogsgaard Thomsen thinks the company's experimental insulins are innovative enough to make a breakthrough.

Photo: Novo Nordisk / PR

For the first time since the insulin market stagnated due to price pressure in the US – forcing Novo Nordisk to book a notorious downgrade in 2016 – the most talked-about drug in Novo Nordisk's diabetes pipeline is once again an insulin.

The drug bears the name insulin icodec and passed its phase 2 studies in June. The drug is special in the sense that patients need only take it once a week rather than one or more times every day.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs